Adjuvant Chemotherapy Considerations+-+-basal cell carcinoma+-+-Triple-Negative Breast Cancer+-+-Metastatic Colorectal Cancer+-+-Standard Chemotherapy Regimens+-+-neoadjuvant chemotherapy+-+-neoadjuvant chemotherapy outcomes+-+-adjuvant setting+-+-sequential anthracycline-taxane chemotherapy+-+-Surgical Adjuvant Breast+-+-breast cancer subtypes.19+-+-Platinum Chemotherapy+-+-Pancreatic Cancer Incidence+-+-intrinsic subtypes+-+-triple-negative disease.21 Docetaxel+-+-residual invasive cancer+-+-pathologic complete response+-+-additional intrinsic subtypes+-+-breast cancers+-+-high response rates+-+-Renal Cell Carcinoma+-+-neoadjuvant regimens+-+-locally advanced TNBC+-+-Adjuvant Settings+-+-OncLive TV+-+-multiple myeloma+-+-advanced basal cell+-+-Overall response rates+-+-metastatic TNBC+-+-recent expression analysis+-+-Daniel G. Stover+-+-slightly lower response+-+-high proliferation-related markers+-+-axillary lymph nodes+-+-important prognostic information+-+-viable first-line option+-+-Sara M. Tolaney+-+-widely studied classification+-+-Dr. Van Morris+-+-commonly used standard+-+-equally represented categories+-+-Conference Coverage+-+-Caitlin F. Bell+-+-long-term outcomes+-+-new regimens+-+-pathway inhibitor vismodegib+-+-potential regimens+-+-dose-dense anthracycline-taxane combination+-+-hormone receptor-negative patients.22+-+-Community Practice Connections+-+-Enzalutamide Pricing Debate+-+-study investigating radiation+-+-ongoing randomized phase+-+-metastatic setting.25-27+-+-metastatic disease.26+-+-DNA repair defects+-+-Inflexible CMS Metrics+-+-Fibroblast Growth Factor+-+-12th Annual International+-+-Relapsed Chronic Lymphocytic+-+-Prefer Pay Cuts+-+-Specialty Pharmacy Times+-+-Heptocellular Carcinoma+-+-Anal Cancer+-+-pathologic response+-+-neoadjuvant chemotherapy.14+-+-TNBC subpopulations+-+-luminal AR+-+-Cancer Summaries+-+-OncLive Insights+-+-Education  CME+-+-sequential therapy+-+-Neck Cancer+-+-Smoldering Myeloma+-+-Potential Treatment+-+-News Network+-+-first-line carboplatin+-+-Interactive Tools+-+-therapy options+-+-Latest Videos+-+-basal-like tumors+-+-long-term prognosis+-+-platinum agents+-+-long-term outcome+-+-OncLive Resources+-+-common regimen+-+-epirubicin-based regimen+-+-single-agent platinum+-+-Plainsboro Road+-+-long-term toxicity+-+-Recent Advances+-+-residual disease+-+-MD Magazine+-+-CME Activities+-+-TNT trial+-+-Diagnostic Workup+-+-Free CME+-+-Latest Articles+-+-Genitourinary Cancers+-+-proto-oncogene c-kit+-+-breast-conserving surgery+-+-phase II trial+-+-Copyright OncLive+-+-Wendy Setiawan+-+-similar improvements+-+-small number+-+-moderate-to-high risk+-+-United States+-+-cross-linking agents8+-+-MJH Associates+-+-disease-free survival+-+-high frequency+-+-Bowel Project+-+-0-1 lines+-+-histologic evidence+-+-concurrent regimens.20+-+-Nursing News+-+-Lenalidomide Examined+-+-New Questions+-+-pre-authorization requirements+-+-Gene expression+-+-Ethnic Populations+-+-cost-sharing arrangements+-+-Cutaneous Malignancies+-+-appropriate surrogate+-+-Education Resource+-+-Chris Barker+-+-Advisory Board+-+-American Journal+-+-Press Releases+-+-Web Exclusives+-+-External Resources+-+-Texas Oncology+-+-Early Intervention+-+-longer duration+-+-Managed Care+-+-lower frequency+-+-Money Digest+-+-Privacy Policy+-+-cyclophosphamide+-+-Therapeutic Target+-+-Page+-+-women+-+-5-fluorouracil+-+-pCR+-+-Exchange+-+-likelihood+-+-goals+-+-Publications+-+-head+-+-TNBCs+-+-LLC+-+-Cortazar+-+-paclitaxel+-+-methotrexate+-+-CMF+-+-meta-analysis+-+-Nivolumab+-+-approach+-+-cytokeratins+-+-EGFR+-+-TNBC.17+-+-point+-+-NSABP+-+-subgroups+-+-adriamycin+-+-Building+-+-Reading+-+-fluorouracil+-+-alternative+-+-Role+-+-data+-+-Rights+-+-Content+-+-AJHO+-+-TargetedOnc+-+-Erivedge+-+-researchers+-+-Revlimid+-+-Contact+-+-quality+-+-Washington+-+-Xtandi+-+-Commentaries+-+-Terms+-+-Conditions+-+-FGFR+-+-Management+-+-Physicians+-+-Physician+-+-oncologists